个人情况介绍、概览
赵明，女，博士，特聘副教授。2017年毕业于沈阳药科大学，获药学学士学位，2020年于沈阳药科大学获药剂学硕士学位，2023年于同校获药剂学博士学位，同年通过沈阳药科大学高层次引进人才政策留校任教，被聘为沈阳药科大学特聘副教授。作为课题负责人主持了辽宁省科技厅项目1项、教育厅项目1项、沈阳药科大学高层次人才引进科研启动项目1项。另外，作为项目骨干成员承担国家自然科学基金面上项目1项。目前，以第一或通讯作者身份在Acta Pharmaceutica Sinica B、Journal of Controlled Release等领域知名期刊发表多篇SCI论文。
人才称号、社会兼职等（限填10项）
1.《沈阳药科大学学报》青年编委
2. 沈阳市拔尖人才
主要研究方向（限填3项）
研究方向一：肿瘤免疫治疗研究
研究方向二：智能响应型纳米递药系统的构建与核酸分子递送研究
主持、参与的科研项目（含科研获奖等情况）（限填10项）
1. 基于调控细胞焦亡与cGAS-STING通路的生物正交纳米反应器用于结肠癌治疗研究，辽宁省科技计划联合计划（自然科学基金-面上项目），基金编号2024-MSLH-436（负责人）
2. 基于三元联动策略的生物正交纳米反应器用于上皮性卵巢癌治疗研究，辽宁省教育厅基本科研项目，基金编号LJ212410163025（负责人）
3. 气体/NIR双驱动前药纳米组装体用于协同溶栓及预防再灌注损伤机制的研究，国家自然科学基金面上项目，基金编号82574359（参与人）
4. 沈阳药科大学高层次人才引进科研启动项目（负责人）
近年来发表代表性论文(限第一作者或通讯作者，SCI须写明影响因子)：（限填10篇）
(1) Saiqing Zheng; Dawei Chen; Ming Zhao*; Haiyang Hu*; The application of nanomedicines in repairing damage in myocardial infarction, Journal of Controlled Release, 2025, 388: 114388. (IF=11.5)
(2) Zhenhua Li; Ziyue Xi; Chuanyong Fan; Xinran Xi; Yao Zhou; Ming Zhao*; Lu Xu*; Nanomaterials Evoke Pyroptosis Boosting Cancer Immunotherapy, Acta Pharmaceutica Sinica B, 2025; 15(2): 852-875. (IF=14.8)
(3) Wenhu Zhu; Fei Wu; Zhanhong Qiao; Ming Zhao*; Haiyang Hu*; Nanomaterials-mediated adenosine pathway inhibition for strengthening cancer immunotherapy, Theranostics, 2025, 15(11): 5007-5028. (IF=13.3)
(4) Bowen Song#; Ziye Zhao#; Zhanhong Qiao; Ji Li; Dawei Chen; Ming Zhao*; Haiyang Hu*; Bacteria-driven Mitoxantrone/Ferric ions liposomes to Synergize Chemotherapy, ferroptosis and immunotherapy for robust antitumor therapy, Journal of Colloid and Interface Science, 2025, 699: 138193. (IF=9.7)
(5) Dazhong Wang#; Meng Yuan#; Ji Liu; Ming Zhao*; Ting Fang*; The application of nanotechnology in regulating mitochondrial function in tumor microenvironment for cancer therapy. Theranostics 2026; 16(1):272-297. (IF=13.3)
(6) Jiaping Liu; Ziyue Xi; Chuanyong Fan; Yihua Mei; Jiale Zhao; Yingying Jiang; Ming Zhao*; Lu Xu*; Hydrogels for nucleic acid drugs delivery, Advanced Healthcare Materials, 2024, 2401895. (IF=9.6)
(7) Ming Zhao#; Ji Li#; Fan Chen; Yanyan Han; Dawei Chen*; Haiyang Hu*; Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation, Journal of Controlled Release, 2023, 355: 211-227. (IF=10.5)
(8) Yuyi Xu#; Ming Zhao#; Jinxue Cao; Ting Fang; Jian Zhang; Yanli Zhen; Fangli Wu; Xiaohui Yu; Yaming Liu; Ji Li*; Dongkai Wang*; Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis, Acta Pharmaceutica Sinica B, 2023, 13: 4417-4441. (IF=14.7)
(9) Ji Li#; Ming Zhao#; Wendi Liang; Siwen Wu; Zheran Wang*; Dongkai Wang*; Codelivery of Shikonin and siTGF-β for enhanced triple negative breast cancer chemo-immunotherapy, Journal of Controlled Release, 2022, 342: 308-320. (IF=10.8)
(10) Ming Zhao#; Ji Li#; Jingwen Liu; Moxi Xu; Hongrui Ji; Siwen Wu; Dawei Chen*; Haiyang Hu*; Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction, Journal of Controlled Release, 2021, 335: 320-332. (IF=11.467)